Novo's next-gen beats Zepbound, Medicare's GLP-1 math, and the compounding squeeze.

1. Novo says its next-gen drug tops Lilly's Zepbound

Novo Nordisk said Monday its next-generation experimental obesity drug CagriSema achieved an estimated 12.4% average weight loss in a late-stage trial and was superior to Eli Lilly's competing drug. The same day, Novo's CEO said the company aims to launch more than five blockbuster drugs by 2030.

Why it matters: the next-generation efficacy race is accelerating. More molecules moving toward approval means more supply options - and new waves of patient demand - heading toward practices.

Source: Reuters, September 21, 2026

2. Medicare's GLP-1 Bridge: 700,000 new patients since July

About 700,000 Medicare beneficiaries have started GLP-1 treatment since the Medicare GLP-1 Bridge launched in July, Lilly CEO Dave Ricks told CNBC - and 70% of them are on Lilly medicines. The program offers a $50 monthly copay, manufacturers supply the drugs at a net price of $245 per monthly supply, and it runs through December 2027. Lilly's oral pill Foundayo now accounts for a third of new oral GLP-1 starts.

Why it matters: GLP-1s keep going mainstream at lower price points. Cash-pay practices need a sharp value story - and total patient volume keeps expanding underneath everyone.

Source: Becker's Hospital Review, September 21, 2026

3. Fifth Circuit upholds FDA: the GLP-1 shortage is legally over

The Fifth Circuit affirmed the FDA's determination that the semaglutide and tirzepatide shortages are over, clearing the agency to keep restricting shortage-era mass compounding. An estimated 1.5 million Americans still use compounded GLP-1s, and the FDA has warned about dosing errors and unverified salt-form ingredients in copycat products.

Why it matters: the enforcement climate around gray-market supply keeps tightening. Practices buying documented, compliant supply are on the right side of where this is heading - and patients pushed off copycat sources will be looking for legitimate channels.

Sources: Forbes, September 21, 2026 · Clark Hill, September 9, 2026

4. States are actually enforcing med-spa rules

State legislators, prosecutors and medical boards are paying closer attention to medical aesthetic practices: new licensure laws (Indiana's responsible-practitioner requirements), "ghost medical director" scrutiny, and surprise inspections. In one example, Ohio fined a med spa $25,000 after a prescription-drug violations investigation.

Why it matters: paperwork discipline - licensure, supervision, sourcing documentation - is turning into a competitive advantage, not overhead.

Sources: Holland & Knight, September 9, 2026 · American Med Spa Association, September 9, 2026

Quick hits

• Novo Nordisk signed a deal worth up to $1.4 billion with Orbis Medicines for oral macrocyclic peptides. BioPharma Dive, September 17
• Eli Lilly presented Phase 3 retatrutide data (TRIUMPH-2) at EASD 2026. September 16
• VIO Med Spa entered South Carolina with a three-unit Charleston agreement. September 21